Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Deloitte
McKesson
Moodys
Mallinckrodt
Harvard Business School
Accenture
Federal Trade Commission
Baxter
UBS

Generated: February 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,495,164

« Back to Dashboard

Summary for Patent: 6,495,164
Title: Preparation of injectable suspensions having improved injectability
Abstract:Injectable compositions having improved injectability. The injectable compositions include microparticles suspended in an aqueous injection vehicle having a viscosity of at least 20 cp at 20.degree. C. The increased viscosity of the injection vehicle that constitutes the fluid phase of the suspension significantly reduces in vivo injectability failures. The injectable compositions can be made by mixing dry microparticles with an aqueous injection vehicle to form a suspension, and then mixing the suspension with a viscosity enhancing agent to increase the viscosity of the fluid phase of the suspension to the desired level for improved injectability.
Inventor(s): Ramstack; J. Michael (Lebanon, OH), Riley; M. Gary I. (Cambridge, MA), Zale; Stephen E. (Hopkinton, MA), Hotz; Joyce M. (Cincinnati, OH), Johnson; Olufunmi L. (Cambridge, MA)
Assignee: Alkermes Controlled Therapeutics, Inc. I (Cambridge, MA)
Application Number:09/577,875
Patent Claim Types:
see list of patent claims
Composition; Process; Use;

Drugs Protected by US Patent 6,495,164

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Alkermes VIVITROL naltrexone FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 021897-001 Apr 13, 2006 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Astrazeneca Ab BYDUREON exenatide synthetic FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 022200-001 Jan 27, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Astrazeneca Ab BYDUREON PEN exenatide synthetic FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 022200-002 Feb 28, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,495,164

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,667,061 Preparation of injectable suspensions having improved injectability ➤ Sign Up
7,371,406 Preparation of injectable suspensions having improved injectability ➤ Sign Up
7,799,345 Preparation of injectable suspensions having improved injectability ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,495,164

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China 1430501 ➤ Sign Up
China 100453067 ➤ Sign Up
Cyprus 1107441 ➤ Sign Up
Cyprus 1117652 ➤ Sign Up
Cyprus 1117734 ➤ Sign Up
Czech Republic 20023848 ➤ Sign Up
Czech Republic 301359 ➤ Sign Up
Germany 60128798 ➤ Sign Up
European Patent Office 1754469 ➤ Sign Up
Denmark 1283699 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Federal Trade Commission
Merck
Cerilliant
Mallinckrodt
Express Scripts
Moodys
Boehringer Ingelheim
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot